製品番号: HY-N0353

Curdione

(別名: (+)-Curdione)

2 Cited Publications

カスタマーレビュー

Based on 2 publication(s) in Google Scholar

Curdione ((+)-Curdione) is an orally active sesquiterpenoid. Curdione inhibits platelet aggregation. Curdione induces ferroptosis in colorectal cancer via m6A methylation mediated by METTL14 and YTHDF2. Curdione inhibits ferroptosis in Isoproterenol (HY-B0468)-induced myocardial infarction by regulating the Keap1/Trx1/GPX4 signaling pathway, suppressing oxidative stress (ROS) and apoptosis. Curdione ameliorates Doxorubicin (HY-15142)-induced cardiotoxicity by inhibiting oxidative stress (ROS) and activating the Nrf2/HO-1 pathway. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Curdione ameliorates Bleomycin (HY-17565A)-induced pulmonary fibrosis by inhibiting TGF-β-induced fibroblast-to-myofibroblast differentiation. Curdione exhibits neuroprotective effects against focal cerebral ischemia-reperfusion injury in rats. Curdione exerts antiproliferative effects against human uterine leiomyosarcoma by targeting IDO1. Curdione protects vascular endothelial cells and atherosclerosis by regulating DNMT1-mediated ERBB4 promoter methylation. Curdione inhibits inducible prostaglandin E2 production (IC₅₀ = 1.1 μM) and cyclooxygenase 2 expression.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.80%
CAS 番号: 13657-68-6
分子式: C₁₅H₂₄O₂
分子量:236.35

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Curdione 構造式

CAS 番号: 13657-68-6

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- 体外実験
- 体内実験
化学情報
Publications (2)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

GPX4

Glutathione Peroxidase アイソフォーム固有の製品をすべて表示 :

GPX1
GPX4

Heme Oxygenase (HO) アイソフォーム固有の製品をすべて表示 :

HO-1
HO-2

TGF-β Receptor アイソフォーム固有の製品をすべて表示 :

Indoleamine 2,3-Dioxygenase (IDO) アイソフォーム固有の製品をすべて表示 :

体外実験

Curdione (12.5-50 μM, 48 h) decreases the cell viability, promotes intracellular ROS production, increases the expression levels of METTL14 and YTHDF2, and decreases the expression levels of SLC7A11, SLC3A2, HOXA13, and GPX4 in CT26 cells^[1].
Curdione (12.5-50 μM, 48 h) decreases GSH concentration, increases MDA, m6A, ferrous iron and LPO levels and increases the mRNA levels of SLC7A11 and HOXA13 in CT26 and SW480 cells^[1].
Curdione (50 μM, 48 h) reduces cellular ROS concentration, Fe²⁺ and MDA levels, and increases GSH activity, induces ferroptosis via m6A modification of the XC system and the methylation transferase METTL14 in shRNA-METTL14 CT26 and SW480 cells^[1].
Curdione (12.5-50 μM, 48 h) induces cell apoptosis, and its apoptosis inhibitors (Z-VAD-FMK (HY-16658B)) have no effect on ferroptosis in SW480 cells^[1].
Curdione (25-100 μM, 24 h) improves the survival rate in Isoproterenol (ISO) (HY-B0468)-induced H9c2 cells, decreases the cell injury in Erastin (HY-15763)-induced H9c2 cells^[2].
Curdione (25-100 μM, 24 h) bounds to Keap1, regulates the Keap1/Trx1/GPX4 signaling pathway in H9c2 cells^[2].
Curdione (100-200 μM) inhibits neutrophil extracellular trap (NET) formation in neutrophils isolated from mouse bone marrow stimulated with Phorbol 12-myristate 13-acetate (PMA) (HY-18739) or pyogenic platelets^[3].
Curdione (160-500 μM, 48 h) does not affect cell viability, inhibits the differentiation of fibroblasts into myofibroblasts, inhibits TGF-β/Smad3 signaling in HPFs^[5].
Curdione (0-500 μM, 12-72 h) reduces cell viability, inhibits the proliferation mediated by IDO1 against SK-UT-1 and SK-LMS-1 cells, with IC₅₀s of 327 and 309.9 μM^[7].
Curdione (0-100 μM, 24 h) induces G2/M phase arrest, apoptosis and autophagy mediated by IDO1 in SK-UT-1 and SK-LMS-1 cells^[7].
Curdione (0-200 μg/mL, 72 h) induces apoptosis, impaires mitochondrial membrane potential occurred in MCF-7 cells (IC₅₀ = 125.632 μg/mL)^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

CT26 cells
Concentration:

12.5 μM, 25 μM, 50 μM
Incubation Time:

48 h
Result:

Increased the expression levels of METTL14 and YTHDF2, and decreased the expression levels of SLC7A11, SLC3A2, HOXA13, and GPX4.

Western Blot Analysis^[1]

Cell Line:

shRNA-METTL14 CT26 and SW480 cells
Concentration:

50 μM
Incubation Time:

48 h
Result:

Increased expression of SLC7A11, HOXA13, SLC3A2 and GPX4.

Apoptosis Analysis^[1]

Cell Line:

SW480 cells
Concentration:

12.5 μM, 25 μM, 50 μM
Incubation Time:

48 h
Result:

Inducted apoptosis, promoted the development of ferroptosis.
Had no statistically significant difference of ferroptosis when combined with Z-VAD-FMK (HY-16658B) (10 μM).

Western Blot Analysis^[2]

Cell Line:

H9c2 cells
Concentration:

100 μmol/L
Incubation Time:

1 h
Result:

Increased the stability of Keap1.

Western Blot Analysis^[2]

Cell Line:

H9c2 cells/ Flag-Keap1, HA-GPX4, and Myc-Trx1 plasmids and tranfected to 293T cells
Concentration:

25 μM, 50 μM, 100 μM
Incubation Time:

24 h
Result:

Inhibited Keap1 expression and increased ISO-induced Trx1 expression, reduced interaction between Keap1 and Trx1 and increased complex between Trx1 and GPX4.

Western Blot Analysis^[5]

Cell Line:

HPFs
Concentration:

160 μM, 300 μM
Incubation Time:

48 h
Result:

Reduced fibronectin, collagen 1, and α-SMA levels.
Attenuated TGF-β1-induced p-Smad3 activation, but not p-Smad2.

RT-PCR^[5]

Cell Line:

HPFs
Concentration:

160 μM, 300 μM
Incubation Time:

48 h
Result:

Reduced fibronectin, collagen 1, and α-SMA levels, increased Smad7 inhibits p-Smad3

Immunofluorescence^[5]

Cell Line:

HPFs
Concentration:

160 μM, 300 μM
Incubation Time:

48 h
Result:

Reduced fibronectin, collagen 1, and α-SMA levels.

Immunofluorescence^[7]

Cell Line:

SK-UT-1 and SK-LMS-1 cells
Concentration:

0 μM, 25 μM, 50 μM, 100 μM
Incubation Time:

24 h
Result:

Reduced the expression of EdU and Ki67.

Cell Cycle Analysis^[7]

Cell Line:

SK-UT-1 and SK-LMS-1 cells
Concentration:

0 μM, 25 μM, 50 μM, 100 μM
Incubation Time:

24 h
Result:

Induced G2/M phase arrest.

Western Blot Analysis^[7]

Cell Line:

SK-UT-1 and SK-LMS-1 cells
Concentration:

0 μM, 25 μM, 50 μM, 100 μM
Incubation Time:

24 h
Result:

Up-regulated the cell cycle checkpoint proteins P21 and CyclinB1 and down-regulated Cdc2.
Increased cleavage of caspase 3, 6, and 9 without affecting caspase 8.
Up-regulateed LC3 and Beclin-1, and down-regulated P62, IDO1.

Apoptosis Analysis^[7]

Cell Line:

SK-UT-1 and SK-LMS-1 cells
Concentration:

0 μM, 25 μM, 50 μM, 100 μM
Incubation Time:

24 h
Result:

Increased the percentage of early and late apoptotic cells and induced cell death.

Apoptosis Analysis^[9]

Cell Line:

MCF-7 cells
Concentration:

0, 25, 50, 100, 150, 200 μg/mL
Incubation Time:

72 h
Result:

Induced apoptosis, increased the expressions of Bax, cleaved caspase-3 and caspase-9, decreased Bcl-2 expression.

体内実験

Curdione (50-200 mg/kg, i.v., once a day, 22 days) inhibits tumor growth, induces ferroptosis mediated by m6A methylation via METTL14 and YTHDF2 in CRC xenograft nude mice^[1].
Curdione (25-100 mg/kg, i.g., once a day, 7 days) attenuates myocardial injury, alleviates ferroptosis via regulating Keap1/Trx1/GPX4 signaling pathway in ISO-induced myocardial infarction male (MI) mice model^[2].
Curdione (50-100 mg/kg, i.p., once) improves lung injury, reduce inflammation and oxidative stress levels, inhibit the activation of MAPK kinase and NF-κB P65, lung neutrophil infiltration and NET formation, regulate platelet activation, and reduce the interaction between neutrophils and platelets in the lungin cecal ligation and puncture (CLP) sepsis mice model^[3].
Curdione (100 mg/kg, i.p., every 2 days, 21 days) reduces pulmonary fibrosis, expression of fibrosis-specific markers, and inhibits differentiation of fibroblasts into myofibroblasts Bleomycin (BLM) (HY-17565A)-induced Idiopathic pulmonary fibrosis (IPF) mouse model^[5].
Curdione (100 mg/kg, i.g., once a day, 7 days) exerts neuroprotective effects against cerebral ischemia/reperfusion-induced brain injury through antioxidant and anti-apoptotic effects middle cerebral artery occlusion (MCAO) SD rats model^[6].
Curdione (100-200 mg/kg, i.p., once a day, 21 days) suppresses the growth of uLMS by targeting IDO1 and activating apoptosis and autophagy in SK-UT-1 xenograft model^[7].
Curdione (50-150 mg/kg, every two days, 16 days) inhibits tumor growth in MCE-7 xenograft BALB/c nude mice model^[9]

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CRC (0.5 × 10⁷, CT26 cells) xenograft nude mice^[1]
Dosage:

50 mg/kg, 100 mg/kg, 200 mg/kg
Administration:

i.v., once a day, 22 days
Result:

Suppressed tumor volume and mass, exhibited pronounced ruffling and nuclear chromatin boundary setting, accompanied by necrosis and fibrosis, and decreased cell density.
Increased iron, MDA, and LPO levels, and decreased GSH levels.
Increased protein expression of METTL14, YTHDF2, SLC7A11, and decreased protein expression levels of SLC3A2, HOXA13, and GPX4.
Increased mRNA expression of YTHDF2, SLC7A11, SLC3A2, HOXA13, and PTGS2 and decreased mRNA expression of GPX4.

Animal Model:

ISO (100 mg/kg)-induced MI C57BL/6 mice (21-25 g, 6-8 weeks) model^[2]
Dosage:

25 mg/kg, 50 mg/kg, 100 mg/kg
Administration:

i.g., once a day, 7 days
Result:

Improved ejection fraction (EF), reduced ISO-increased CK-MB levels, restored normal muscle fiber structure, and reduced the degree of inflammatory cell infiltration in cardiac tissue.
Lowered MDA and iron levels and increaseed GSH, GPX4, FTH1 levels.
Inhibited Keap1 expression and increased ISO-induced Trx1 expression.

Animal Model:

CLP sepsis mice (8-10 weeks old, Male) model^[3]
Dosage:

50 mg/kg, 100 mg/kg
Administration:

i.p., once
Result:

Reduced lung congestion, alveolar wall thickening, and inflammatory cell infiltration in lung sections, reduced lung injury scores, pulmonary edema, and reduced exudate protein levels in BALF and lung W/D ratio, as well as LDH activity in BALF.
Reduced CLP-induced increases in DHE and MDA, increased superoxide dismutase (SOD) levels, and decreased IL-1β, IL-6, and TNF-α levels in BALF.
Inhibited the phosphorylation of MAPK kinase and NF-κB P65, and reduced the activation of NF-κB P65.
Reduced CXCL4 and CXCL7 in BALF and reduced platelet activation in lung tissue.
Decreased MPO-positive neutrophils, total cell counts in BALF, and the number of infiltrating neutrophils in BALF.
Reduced fluorescence intensity of platelet activation markers CD42d/GP5, neutrophil marker Ly6G and the formation of NETs in the lungs.

Animal Model:

BLM-induced IPF mouse (8 weeks old, male) model^[5]
Dosage:

100 mg/kg
Administration:

i.p., every 2 days, 21 days
Result:

Reduced lung injury, lung fibrosis, and inflammatory cell (lymphocyte and macrophage) infiltration levels, reduced hydroxyproline content.
Reduced protein and mRNA expression levels of fibronectin, collagen 1, and α-SMA.
Reduced α-SMA positive cells and reduced fibroblast differentiation.

Animal Model:

MCAO SD rats (240-270 g, adult male) model^[6]
Dosage:

100 mg/kg
Administration:

i.g., once a day, 7 days
Result:

Reduced infarct size and neurological deficits and promoted motor function and cognitive function recovery.
Reversed the obvious pathological abnormalities of the MCAO group, including loose arrangement of neurons, nuclear consolidation, loss of color staining or dark color.
Increased the activities of SOD, CAT and GSH-PX, suppressed the increase in the MDA content caused by the injury with cerebral ischemia/reperfusion.
Down-regulated Bax expression and up-regulated Bcl-2 expression, thereby increasing the Bcl-2/Bax ratio, reduced Cyt-C, c-caspase-3, and c-caspase-9 protein levels.

Animal Model:

SK-UT-1 (1 × 10⁷) xenograft BALB/c nude mice (6-7 weeks, female, 18 g) model^[7]
Dosage:

100 mg/kg, 200 mg/kg
Administration:

i.p., once a day, 21 days
Result:

Exhibited anti-uLMS growth efficacy with minimal systemic toxicity, down-regulated IDO1, ki67, and p62, and up-regulated the cleaved caspase-3, Beclin1 and LC3 in tumor tissues.

Animal Model:

MCE-7 (1 × 10⁷) xenograft BALB/c nude mice (5-6 weeks, female, 20 g) model^[9]
Dosage:

50 mg/kg, 100 mg/kg, 150 mg/kg
Administration:

every two days, 16 days
Result:

Inhibited tumor growth.

化学情報

CAS 番号 13657-68-6
性状 Solid
分子量 236.35
分子式 C₁₅H₂₄O₂
Color White to off-white
SMILES

O=C1C[C@@H](C(C)C)C(C/C(C)=C/CC[C@@H]1C)=O
別名

(+)-Curdione
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

Front Cell Dev Biol

Curdione and Schisandrin C Synergistically Reverse Hepatic Fibrosis via Modulating the TGF-β Pathway and Inhibiting Oxidative Stress. [Abstract]

2021 Nov 10;9:763864. PMID: 34858986
Tohoku J Exp Med

Curdione Suppresses Non-Small Cell Lung Cancer Growth by Inducing Ferroptosis. [Abstract]

2025 Nov 13. PMID: 41224330

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (423.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.2310 mL

21.1551 mL

42.3101 mL

5 mM

0.8462 mL

4.2310 mL

8.4620 mL

10 mM

0.4231 mL

2.1155 mL

4.2310 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.75 mg/mL (11.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.75 mg/mL (11.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.75 mg/mL (11.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (303 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Wang F, et al. Curdione induces ferroptosis mediated by m6A methylation via METTL14 and YTHDF2 in colorectal cancer. Chin Med. 2023 Sep 21;18(1):122. [Content Brief]

[2]. Wang H, et al. Curdione inhibits ferroptosis in isoprenaline-induced myocardial infarction via regulating Keap1/Trx1/GPX4 signaling pathway. Phytother Res. 2023 Nov;37(11):5328-5340. [Content Brief]

[3]. Yang K, et al. Curdione ameliorates sepsis-induced lung injury by inhibiting platelet-mediated neutrophil extracellular trap formation. Int Immunopharmacol. 2023 May;118:110082. [Content Brief]

[4]. Ma Y, et al. Curdione Relieved Isoproterenol-Induced Myocardial Damage through Inhibiting Oxidative Stress and Apoptosis. Am J Chin Med. 2023;51(1):73-89. [Content Brief]

[5]. Liu P, et al. Curdione ameliorates bleomycin-induced pulmonary fibrosis by repressing TGF-β-induced fibroblast to myofibroblast differentiation. Respir Res. 2020 Feb 19;21(1):58. [Content Brief]

[6]. Li XJ, et al.Neuroprotective effects of curdione against focal cerebral ischemia reperfusion injury in rats. Neuropsychiatr Dis Treat. 2017 Jun 30;13:1733-1740. [Content Brief]

[7]. Wei C, et al. Curdione Induces Antiproliferation Effect on Human Uterine Leiomyosarcoma via Targeting IDO1. Front Oncol. 2021 Feb 26;11:637024. [Content Brief]

[8]. Wu Z, Zai W, Chen W, Han Y, Jin X, Liu H. Curdione Ameliorated Doxorubicin-Induced Cardiotoxicity Through Suppressing Oxidative Stress and Activating Nrf2/HO-1 Pathway. J Cardiovasc Pharmacol. 2019 Aug;74(2):118-127. [Content Brief]

[9]. Li J, et al. Curdione inhibits proliferation of MCF-7 cells by inducing apoptosis. Asian Pac J Cancer Prev. 2014;15(22):9997-10001. [Content Brief]

[10]. Xia Q, Wang X, Xu DJ, Chen XH, Chen FH. Inhibition of platelet aggregation by curdione from Curcuma wenyujin essential Oil. Thromb Res. 2012 Sep;130(3):409-14. [Content Brief]

[11]. Wu Y, et al. Curdione protects vascular endothelial cells and atherosclerosis via the regulation of DNMT1-mediated ERBB4 promoter methylation. Open Med (Wars). 2025 Jul 14;20(1):20251223. [Content Brief]

[12]. Oh OJ, et al. Inhibition of inducible prostaglandin E2 production and cyclooxygenase-2 expression by curdione from Curcuma zedoaria. Arch Pharm Res. 2007 Oct;30(10):1236-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.2310 mL	21.1551 mL	42.3101 mL	105.7753 mL
	5 mM	0.8462 mL	4.2310 mL	8.4620 mL	21.1551 mL
	10 mM	0.4231 mL	2.1155 mL	4.2310 mL	10.5775 mL
	15 mM	0.2821 mL	1.4103 mL	2.8207 mL	7.0517 mL
	20 mM	0.2116 mL	1.0578 mL	2.1155 mL	5.2888 mL
	25 mM	0.1692 mL	0.8462 mL	1.6924 mL	4.2310 mL
	30 mM	0.1410 mL	0.7052 mL	1.4103 mL	3.5258 mL
	40 mM	0.1058 mL	0.5289 mL	1.0578 mL	2.6444 mL
	50 mM	0.0846 mL	0.4231 mL	0.8462 mL	2.1155 mL
	60 mM	0.0705 mL	0.3526 mL	0.7052 mL	1.7629 mL
	80 mM	0.0529 mL	0.2644 mL	0.5289 mL	1.3222 mL
	100 mM	0.0423 mL	0.2116 mL	0.4231 mL	1.0578 mL

Curdione

2 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Curdione

Covalent Screening Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Coagulation and Anti-coagulation Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cysteine Targeted Covalent Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

MedChemExpress（MCE）の使用を引用している文献 Curdione

Glutathione Peroxidase アイソフォーム固有の製品をすべて表示

Heme Oxygenase (HO) アイソフォーム固有の製品をすべて表示

TGF-β Receptor アイソフォーム固有の製品をすべて表示

Indoleamine 2,3-Dioxygenase (IDO) アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (2)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Curdione 関連分類

HY-N0353 関連分類